Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash & Equivalents (2016 - 2025)

iBio (IBIO) has disclosed Cash & Equivalents for 16 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 310.0% to $28.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, up 310.0% year-over-year, with the annual reading at $8.6 million for FY2025, 39.61% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $28.7 million at iBio, up from $28.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $84.6 million in Q1 2021, with the low at $1.5 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $22.9 million, with a median of $10.5 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 742.9% in 2021, then crashed 90.57% in 2022.
  • Over 5 years, Cash & Equivalents stood at $39.2 million in 2021, then tumbled by 90.57% to $3.7 million in 2022, then dropped by 24.57% to $2.8 million in 2023, then soared by 151.08% to $7.0 million in 2024, then skyrocketed by 310.0% to $28.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $28.7 million, $28.1 million, and $8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.